Health canada grants approval for ocaliva&#8482 (obeticholic acidity) to treat patients with primary biliary cholangitis (pbc) (nasdaq:icpt)

NEW You are able to, May 25, 2017 (GLOBE NEWSWIRE) — Intercept Pharmaceuticals, Corporation. (Nasdaq:ICPT), a biopharmaceutical company centered on the event and commercialization of novel therapeutics to deal with progressive non-viral liver illnesses, today announced that Health Canada grants a conditional approval for Ocaliva (obeticholic acidity) to treat primary biliary cholangitis (PBC), when in combination with ursodeoxycholic acidity (UDCA) in grown-ups by having an insufficient reaction to UDCA or as monotherapy in grown-ups not able to tolerate UDCA.

PBC is really a rare, progressive, autoimmune cholestatic liver ailment that puts patients in danger of existence-threatening complications, affecting an believed 11,000 Canadians. PBC impacts individuals the best of the lives and it is the key reason for liver transplantation among women in Canada.

Ocaliva is really a farnesoid X receptor (FXR) agonist which will fill an essential unmet requirement for patients who’ve an insufficient reaction to, or are not able to tolerate, the grade of care, UDCA, and for that reason stay at considerably elevated chance of liver failure, requirement for liver transplantation, or dying.

"A considerable quantity of PBC people are not achieving treatment goals with UDCA alone along with a couple of cannot tolerate this standard of care. Until we now have only had experimental adjunctive therapies to assist these non-responders with progressive disease," stated Andrew Mason, MBS, FRCPI, Director of Research for that Division of Gastroenterology and Hepatology in the College of Alberta. "The development of Ocaliva will assist you to address this critical need and supply an chance for physicians to revisit treatment goals using their patients."

Ocaliva continues to be issued an advertising and marketing authorization with conditions (also referred to as a Notice of Compliance with Conditions or NOC/c) from Health Canada, pending the outcomes of trials to ensure its clinical benefit. Products approved under Health Canada’s NOC/c policy have shown promising benefit, are of top quality and have a suitable safety profile with different benefit/risk assessment. Further, Health Canada approval follows an faster priority overview of the Ocaliva New Drug Submission, recognizing the unmet requirement for new therapies in PBC.

"We’re excited to become presenting the very first new treatment choice for PBC in over twenty years for Canadian patients so carefully following regulatory approval within the U.S. and Europe," stated Mark Pruzanski, M.D., President and Chief executive officer of Intercept. "Health Canada’s approval is encouraging news for patients to represent another essential part of Intercept’s pursuit to enhance the lives of individuals with progressive non-viral liver illnesses."

Intercept is positively going after reimbursement of Ocaliva with private insurance companies and public drug plans across Canada. Intercept is dedicated to making certain patients with PBC have access to Ocaliva as rapidly and simply as you possibly can and it has launched the Navigate™ Patient Support Program to supply comprehensive and personalized support for qualified patients prescribed Ocaliva for PBC.

"We’re very excited that Canadians coping with PBC will come with an important new treatment option," stated Gail Wright, President from the Canadian PBC Society. "It’s this type of promising here we are at PBC patients, and also the community continues to be energized by new advances in research, growing disease awareness one of the public and clinicians and today the development of a significantly-needed new therapy to assist patients better manage their disease."

About Primary Biliary Cholangitis

Primary biliary cholangitis (PBC) is really a rare, autoimmune cholestatic liver ailment that puts patients in danger of existence-threatening complications. PBC is mainly an illness of ladies, afflicting roughly one out of 1,000 women older than 40. If not treated, survival of PBC patients is considerably worse compared to general population.

About Ocaliva™ (obeticholic acidity)

Ocaliva (obeticholic acidity) is definitely an agonist from the farnesoid X receptor (FXR), a nuclear receptor expressed within the liver and intestine. FXR is really a key regulator of bile acidity, inflammatory, fibrotic and metabolic pathways.

Ocaliva is suggested for Canada to treat primary biliary cholangitis (PBC) in conjunction with ursodeoxycholic acidity (UDCA) in grown-ups by having an insufficient reaction to UDCA, or as monotherapy in grown-ups not able to tolerate UDCA. Ocaliva continues to be issued an advertising and marketing authorization with conditions from Health Canada, pending the outcomes of trials to ensure its clinical benefit.

In May 2016, the U.S. Fda granted faster approval to Ocaliva to treat PBC. In December 2016, Ocaliva received conditional marketing authorization in Europe in the European Medicines Authority.

CANADIAN IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Patients who’re sensitive for this drug in order to any component within the formulation or element of the container. Ocaliva is contraindicated in patients with complete biliary obstruction.

WARNINGS AND Safeguards

Liver-Related Side Effects

In 2 3-month, placebo-controlled numerous studies, a serving-response relationship was observed for the appearance of liver-related side effects including jaundice, worsening ascites and first biliary cholangitis flare with dosages of Ocaliva of 10 mg once daily to 50 mg once daily (as much as 5-occasions the greatest suggested dosage), as soon as 30 days after beginning treatment with Ocaliva.

Monitor patients during treatment with Ocaliva for elevations in liver biochemical tests and to add mass to liver-related side effects. Weigh the hazards against the advantages of ongoing treatment with Ocaliva in patients who’ve experienced clinically significant liver-related side effects. Discontinue Ocaliva in patients who develop complete biliary obstruction.

Severe Pruritus

Pruritus was mostly mild to moderate in severity and usually began inside the first month following a initiation of treatment with Ocaliva and decreased in severity with time with ongoing dosing. Severe pruritus was reported in 23% of patients within the Ocaliva 10 mg arm, 19% of patients within the Ocaliva titration arm, and sevenPercent of patients within the placebo arm, correspondingly. Management strategies include adding bile acidity resins or antihistamines, Ocaliva dosage reduction, and/or temporary interruption of Ocaliva dosing.

Side Effects

The most typical adverse drug reactions reported in double-blind numerous studies (frequency&ge5%) were pruritus, fatigue, constipation, oropharyngeal discomfort and arthralgia.

For detailed safety information for Ocaliva (obeticholic acidity) 5 mg and 10 mg tablets please visit the merchandise Monograph.

About Intercept Pharma Canada Corporation.

Intercept Pharma Canada Corporation. may be the Canadian subsidiary of Intercept Pharmaceuticals, Corporation., founded in 2015 and located in Mississauga, Ontario. Intercept is really a proud person in Ontario’s biopharmaceutical community, and it is dedicated to helping support the requirements of Canada’s liver health community.

About Intercept

Intercept is really a biopharmaceutical company centered on the event and commercialization of novel therapeutics to deal with progressive non-viral liver illnesses, including primary biliary cholangitis (PBC), nonalcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC) and biliary atresia. Founded in 2002 in New You are able to, Intercept presently has operations within the U . s . States, Europe and Canada. Intercept’s Worldwide headquarters come in London. To learn more about Intercept, check out www.interceptpharma.com.

Safe Harbor Statements

This pr release contains "forward-searching statements" inside the concept of the non-public Securities Litigation Reform Act of 1995, including, although not restricted to, statements concerning the clinical relevance and utility of ALP, bilirubin and also the surrogate endpoint utilized in the Phase 3 POISE trial to calculate clinical outcomes, the acceptance of OcalivaTM (obeticholic acidity) like a strategy to PBC by healthcare providers, patients and payors, the commercial accessibility to OCA to treat PBC and timelines related thereto, the anticipated prevalence of along with other epidemiological estimates and market data associated with PBC, and our proper directives underneath the caption "About Intercept." These "forward-searching statements" derive from management’s current expectations of future occasions and therefore are susceptible to numerous important risks and uncertainties that may cause actual leads to differ materially and adversely from individuals established in or implied by such forward-searching statements. These risks and uncertainties include, but aren’t restricted to: Intercept’s capability to effectively commercialize Ocaliva in PBC, and Intercept’s capability to maintain its regulatory approval in jurisdictions by which Ocaliva qualifies to be used in PBC the initiation, cost, timing, progress and outcomes of Intercept’s development activities, preclinical studies and numerous studies the timing of and Intercept’s capability to obtain and keep regulatory approval of OCA in PBC in countries outdoors those that qualifies as well as in indications apart from PBC and then any other product candidates it might develop for example INT-767 conditions which may be enforced by regulatory government bodies on Intercept’s marketing approvals because of its products and product candidates like the requirement for clinical outcomes data (and not simply results according to achievement of the surrogate endpoint), and then any related limitations, limitations, and/or warnings within the label associated with a approved products and product candidates Intercept’s intends to research, develop and commercialize its product candidates Intercept’s capability to obtain and keep ip protection because of its products and product candidates Intercept’s capability to effectively commercialize its products and product candidates the dimensions and development of the markets for Intercept’s products and product candidates and how it can serve individuals markets the speed and amount of market acceptance associated with a of Intercept’s products, which can be impacted by the reimbursement caused by payors the prosperity of competing drugs which are or become available regulatory developments within the U . s . States along with other countries the performance of third-party suppliers and manufacturers the election by Intercept’s collaborators to pursue research, development and commercialization activities Intercept’s capability to attract collaborators with development, regulatory and commercialization expertise Intercept’s requirement for and skill to obtain more financing Intercept’s estimates regarding expenses, revenues and capital needs and also the precision thereof Intercept’s utilization of cash and short-term investments Intercept’s capability to attract and retain key scientific or management personnel along with other factors discussed underneath the heading "RisksInch found in our annual set of Form 10-K for that year ended December 31, 2016 filed on March 1, 2017 in addition to any updates to those risks filed every so often within our other filings using the Registration. Information within this pr release is really as from the date from the release, and Intercept undertakes no duty to update these details unless of course needed legally.

Contact

To learn more about Intercept Pharmaceuticals, please contact:

Mark Vignola

+1-646-747-1000

investors@interceptpharma.com

Christopher Frates

+1-646-757-2371

media@interceptpharma.com

Resourse: http://ir.interceptpharma.com/